UNLABELLED: Viral infections are often linked to altered drug metabolism in patients; however, the underlying molecular mechanisms remain unclear. Here we describe a mechanism by which activation of antiviral responses by the synthetic double-stranded RNA ligand, polyinosinic-polycytidylic acid (polyI:C), leads to decreased acetaminophen (APAP) metabolism and hepatotoxicity. PolyI:C administration down-regulates expression of retinoic X receptor-α (RXRα) as well as its heterodimeric partner pregnane X receptor (PXR) in mice. This down-regulation results in suppression of downstream cytochrome P450 enzymes involved in conversion of APAP to its toxic metabolite. Although the effects of polyI:C on drug metabolism are often attributed to interferon production, we report that polyI:C can decrease APAP metabolism in the absence of the type I interferon receptor. Furthermore, we demonstrate that polyI:C can attenuate APAP metabolism through both its membrane-bound receptor, Toll-like receptor 3 (TLR3), as well as cytoplasmic receptors. CONCLUSION: This is the first study to illustrate that in vivo administration of polyI:C affects drug metabolism independent of type I interferon production or in the absence of TLR3 through crosstalk between nuclear receptors and antiviral responses.
UNLABELLED: Viral infections are often linked to altered drug metabolism in patients; however, the underlying molecular mechanisms remain unclear. Here we describe a mechanism by which activation of antiviral responses by the synthetic double-stranded RNA ligand, polyinosinic-polycytidylic acid (polyI:C), leads to decreased acetaminophen (APAP) metabolism and hepatotoxicity. PolyI:C administration down-regulates expression of retinoic X receptor-α (RXRα) as well as its heterodimeric partner pregnane X receptor (PXR) in mice. This down-regulation results in suppression of downstream cytochrome P450 enzymes involved in conversion of APAP to its toxic metabolite. Although the effects of polyI:C on drug metabolism are often attributed to interferon production, we report that polyI:C can decrease APAP metabolism in the absence of the type I interferon receptor. Furthermore, we demonstrate that polyI:C can attenuate APAP metabolism through both its membrane-bound receptor, Toll-like receptor 3 (TLR3), as well as cytoplasmic receptors. CONCLUSION: This is the first study to illustrate that in vivo administration of polyI:C affects drug metabolism independent of type I interferon production or in the absence of TLR3 through crosstalk between nuclear receptors and antiviral responses.
Authors: Guoli Dai; Nathan Chou; Lin He; Maxwell A Gyamfi; Alphonse J Mendy; Angela L Slitt; Curtis D Klaassen; Yu-Jui Y Wan Journal: Mol Pharmacol Date: 2005-09-12 Impact factor: 4.436
Authors: Kristina K Wolf; Sheryl G Wood; Jane A Hunt; Brooke W Walton-Strong; Kazuto Yasuda; Lubin Lan; Su X Duan; Qin Hao; Steven A Wrighton; Elizabeth H Jeffery; Ronald M Evans; Juliana G Szakacs; Lisa L von Moltke; David J Greenblatt; Michael H Court; Erin G Schuetz; Peter R Sinclair; Jacqueline F Sinclair Journal: Drug Metab Dispos Date: 2005-09-01 Impact factor: 3.922
Authors: Brian D Rudd; Jetse J Smit; Richard A Flavell; Lena Alexopoulou; Matthew A Schaller; Achim Gruber; Aaron A Berlin; Nicholas W Lukacs Journal: J Immunol Date: 2006-02-01 Impact factor: 5.422
Authors: Anne-Marie Bleau; Patrick Maurel; Vincent Pichette; François Leblond; Patrick du Souich Journal: Eur J Pharmacol Date: 2003-07-25 Impact factor: 4.432
Authors: Anne P Beigneux; Arthur H Moser; Judy K Shigenaga; Carl Grunfeld; Kenneth R Feingold Journal: Biochem Biophys Res Commun Date: 2002-04-26 Impact factor: 3.575
Authors: Tao Li; Ruth T Yu; Annette R Atkins; Michael Downes; Robert H Tukey; Ronald M Evans Journal: Expert Opin Ther Targets Date: 2012-08-23 Impact factor: 6.902
Authors: Karen A Cavassani; Ana Paula Moreira; David Habiel; Toshihiro Ito; Ana Lucia Coelho; Ron M Allen; Bin Hu; Janna Raphelson; William F Carson; Matthew A Schaller; Nicholas W Lukacs; M Bishr Omary; Cory M Hogaboam; Steven L Kunkel Journal: PLoS One Date: 2013-06-07 Impact factor: 3.240